Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its Entresto heart failure therapy.
Novartis slightly raises 2025 earnings forecast, citing strong Q2
Novartis on Thursday posted a slightly more optimistic full-year earnings forecast, citing the strong growth of drugs such as breast cancer drug Kisqali during the second quarter.
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.
Exploring Analyst Estimates for Novartis (NVS) Q2 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Why Novartis Is Still A 'Buy' After 15% Surge
Despite Trump's hot take toward the pharmaceutical industry and his hard stance on U.S. trading partners, Novartis' share price continues to rise. The main contributors to maintaining bullish sentiment towards the Swiss pharmaceutical behemoth are the strong performance of its cardiovascular, oncology, and immunology franchises. For example, sales of its blockbuster Cosentyx amounted to $1.53 billion in the first three months of 2025, up 15.7% year-on-year.
Novartis loses bid to block US Entresto generic through 2026
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Novartis: A SWAN Worth Owning
Novartis AG could be a qualitative investment with a margin of safety. The drugmaker arguably has the balanced commercial drug portfolio and drug pipeline needed to sustain growth in the years ahead. Novartis carries a very manageable debt load for a company of its size.
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
